Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuBase Therapeutics Inc.

0.3780
0.0000
Volume:- -
Turnover:- -
Market Cap:1.42M
PE:-0.03
High:0.3780
Open:0.3780
Low:0.3780
Close:0.3780
52wk High:0.3780
52wk Low:0.3780
Shares:3.75M
Float Shares:3.32M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-15.0087
EPS(LYR):-20.7937
ROE:-93.46%
ROA:-43.03%
PB:0.10
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
NeuBase Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.